Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Colchicine  COVID-19 treatment studies for Colchicine  C19 studies: Colchicine  Colchicine   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 13% Improvement Relative Risk ICU admission 16% Hospitalization time 25% Karakaş et al. Colchicine for COVID-19 LATE TREATMENT Is late treatment with colchicine beneficial for COVID-19? Retrospective 336 patients in Turkey Shorter hospitalization with colchicine (p=0.0001) Karakaş et al., The J. Infection in Developing C.., doi:10.3855/jidc.14924 Favors colchicine Favors control
Reducing length of hospital stay with colchicine
Karakaş et al., The Journal of Infection in Developing Countries, doi:10.3855/jidc.14924
Karakaş et al., Reducing length of hospital stay with colchicine, The Journal of Infection in Developing Countries, doi:10.3855/jidc.14924
Jan 2022   Source   PDF  
  All Studies   Meta
Retrospective 356 hospitalized COVID-19 patients, shorter hospitalization time with colchicine treatment. There were no statistically significant differences for mortality or ICU admission. Significantly lower mortality was seen with higher dosage (1mg/day vs 0.5mg/day). More control patients were on oxygen at baseline (65% vs. 54%). This study is excluded in the after exclusion results of meta analysis: excessive unadjusted differences between groups.
risk of death, 12.7% lower, RR 0.87, p = 0.72, treatment 16 of 165 (9.7%), control 19 of 171 (11.1%), NNT 71.
risk of ICU admission, 16.0% lower, RR 0.84, p = 0.50, treatment 30 of 165 (18.2%), control 37 of 171 (21.6%), NNT 29.
hospitalization time, 25.0% lower, relative time 0.75, p < 0.001, treatment 165, control 171.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Karakaş et al., 31 Jan 2022, retrospective, Turkey, peer-reviewed, 11 authors, dosage 1mg daily, 0.5mg for 37 patients.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperColchicineAll
Abstract: Coronavirus Pandemic Reducing length of hospital stay with colchicine Özlem Karakaş1, Abdulsamet Erden1, Serdar Can Güven1, Berkan Armağan1, Enes Seyda Sahiner2,3, Ali Can Kurtipek2,3, Osman Inan2,3, Emin Gemcioglu2,3, İhsan Ateş2, Ahmet Omma1, Orhan Küçüksahin1,4 1 Department of Rheumatology, Ankara City Hospital, Ankara, Turkey 2 Department of Internal Medicine, Ankara City Hospital, Ankara, Turkey 3 Ministry of Health, Ankara, Turkey 4 Division of Rheumatology, Department of Internal Medicine, Yıldırım Beyazıt University, Ankara, Turkey Abstract Introduction: Colchicine is an ancient agent with well-known anti-inflammatory effects and commonly used in treatment of hyperinflammatory conditions. It has been argued that colchicine could be an appropriate treatment option in COVID-19 to control hyperinflammatory response. Here in this study, we aimed to investigate the impact of colchicine on outcomes of COVID-19 in our inpatient cohort. Methodology: In this retrospective cohort study, hospitalized COVID-19 patients were investigated. Demographics, comorbidities, COVID19 symptoms, laboratory findings on admission and discharge, baseline and seventh day oxygenation status, rates of mortality, intensive care unit admission, administration of other anti-inflammatory treatments and length of hospital stay were compared between patients who received standard of care medications and who received colchicine additionally. Results: Three hundred and thirty-six patients were included in the study (171 standard of care, 165 standard of care plus colchicine). The median length of hospital stay in colchicine group was significantly shorter. Rates of admission to intensive care unit, anti-inflammatory treatment administration and mortality did not differentiate between standard of care and colchicine groups. However, reduced rates of mortality and ICU admission were observed in patients who received colchicine with a dose of 1 mg/day when compared to patients who received 0.5 mg/day. Conclusions: Our study demonstrated that COVID-19 patients who received colchicine in addition to standard of care had shorter hospital stay. Our results further support the use of colchicine in treatment of COVID-19, particularly with a dose of 1 mg/day. Key words: COVID-19; colchicine; outcome; mortality; hospitalization. J Infect Dev Ctries 2022; 16(1):57-62. doi:10.3855/jidc.14924 (Received 17 February 2021 – Accepted 14 June 2021) Copyright © 2022 Karakaş et al. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop